63
On 8 August 2023, the UK Competition Appeal Tribunal (“CAT”) delivered its judgment upholding the decision by the UK Competition and Markets Authority (“CMA”) against pharmaceutical company Advanz Pharma and its former owners Hg and Cinven (jointly, “Advanz”) for excessive pricing (see VBB on (...)